PAVmed Inc. (PAVM)

Market Cap	18.46M +72.5%
Revenue (ttm)	112,000 -89.0%
Net Income	-20.63M
EPS	-9.85
Shares Out	6.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,243
Open	2.610
Previous Close	2.690
Day's Range	2.580 - 2.810
52-Week Range	2.580 - 28.440
Beta	0.70
Analysts	Buy
Price Target	36.50 (+1,282.58%)
Est. Earnings	Nov 12, 2026

About PAVM

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 28, 2016
• Employees: 41
• Stock Exchange: Nasdaq
• Ticker Symbol: PAVM
• Website: https://www.pavmed.com

Analyst Summary

According to 2 analysts, the average rating for PAVM stock is "Buy." The 12-month stock price target is $36.5, which is an increase of 1,282.58% from the latest price.

Price Target

$36.5

(1,282.58% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 14, 2026

Data Sources Report a data error